A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Program Bookmark and Share

Program

SUNDAY, MARCH 1, 2015

Session 1: Diabetes complications: New biomarkers and drug targets (12:00 pm to 2:00 pm)
  • New treatments for diabetic complications: Results from high throughtput screening and in silico modeling (A. Schmidt, NYU Langone Medical Center)
  • New therapies and biomarkers for diabetic complications: Lessons learnt from omics profiling (K. Sharma, University of California San Diego)
  • RAGE and retinal disease: Roles in diabetic retinopathy (A. Stitt, Queen's University Belfast)
  • Transcription factor acetylation in diabetic glomerulopathy (J. He, Mount Sinai Hospital)
 
Session 2: Personalized medicine in future diabetes care (2:20 pm to 4:20 pm)
  • Personalized medicine: The future is now (E. Bottinger, Icahn School of Medicine Mount Sinai)
  • Using public big-data to discover new therapeutic and genetic insights in diabetes (A. Butte, University of California San Francisco)
  • Pharmacogenetics and precision medicine in type 2 diabetes: Potential implications for clinical practice (J. Florez, Massachusetts General Hospital)
  • Systems genetics of diabetic nephropathy (M. Kretzler, University of Michigan)

Oral Presentations (4:30 pm)
 
Presentation of Awards and Dinner Lecture (6:30 pm)
  • Type 1 diabetes: Adults vs. kids (C. Greenbaum, Benaroya Research Institute)

MONDAY, MARCH 2, 2015
 
Rachmiel Levine Award Lecture (7:30 am)
  • Evolving concepts of incretin action inform the treatment of metabolic disorders (D. Drucker, Lunenfeld Tanenbaum Research Institute)
 
Session 1: Epigenetics of diabetes (8:00 am to 10:00 am)
  • Epigenomics of insulin resistance (E. Rosen, Beth Israel Deaconess Medical Center)
  • Epigenetic mechanisms in diabetic complications and metabolic memory (R. Natarajan, Beckman Research Institute of City of Hope)
  • Hyperglycemia-induced Dnmt activity leading to diabetic embryopathy (M. Loeken, Joslin Diabetes Center)
  • Epigenetics and beta cell identity (M. Sander, University of California San Diego)
 
Session 2: Obesity and inflammation (10:20 am to 12:20 pm)
  • Obesity and immune system (M. Bluher, University Hospital Leipzig)
  • Macrophage lysosome dysfunction in diabetic inflammation (J. Schilling, Washington University)
  • Macrophages, insulin resistance and immunometabolism (A. Ferrante, Columbia University)
  • Macrophages and vitamin D metabolism in diabetes (C. Bernal-Mizrachi, Washington University)
 
Session 3: Metabolism and inflammation (1:30 pm to 3:30 pm)
  • Metabolic signatures in the development of insulin resistance (C. Newgard, Duke University)
  • Epigenetics, metabolism and the circadian clock (P. Sassone-Corsi, University of California Irvine)
  • Innate mechanisms of metabolic homeostasis (A. Chawla, University of California San Francisco)
  • Targeting neuroinflammation for diabetes treatment (M. Tschop, Helmholtz Diabetes Center)
 
Debate: Can adult human beta cells proliferate? (3:50 pm to 5:00 pm)
  • (A. Stewart, Mount Sinai School of Medicine)
  • (D. Harlan, University of Massachusetts)
 
Plenary Lecture (5:00 pm to 5:35 pm)
  • 30 year history of the DCCT: Patient pursuit of a chronic disease (D. Nathan, Massachusetts General Hospital)
 
Poster Session (5:35 pm)

TUESDAY, MARCH 3, 2015
 
Session 1: Lessons from human insulinoma for beta cell regeneration (8:00 am to 10:00 am)
  • The role of YY1 in human insulinoma pathogenesis (G. Ning, Shanghai Institute for Endocrine and Metabolic Diseases)
  • Novel insulinoma-genic molecular pathways (T. Carling, Yale University)
  • RNA profiling of human insulinomas for beta cell regeneration strategies (A. Stewart, Mount Sinai School of Medicine)
  • Non-coding genome function in the developing human pancreas (J. Ferrer, Imperial College London)
 
Session 2: Novel molecules that induce human beta cell replication (10:20 am to 12:20 pm)
  • Liver-derived beta cell regenerative factors (R. Kulkarni, Joslin Diabetes Center)
  • Novel therapeutic epigenetic modulators of human beta cell replication (A. Bhushan, University of California San Francisco)
  • Small-molecule inducers of human beta-cell proliferation (B. Wagner, Broad Institute)
  • High-throughput screening for small-molecule inducers of beta-cell proliferation (P. Wang, Mount Sinai School of Medicine)
 
Arthur Riggs Award Lecture (1:40 pm)
  • The new biology of beta cell failure (D. Accili, Columbia University)
 
Session 3: Reprogramming islet cells to beta cells (2:10 pm to 3:10 pm)
  • In vivo induction of alpha-cell-mediated beta-like cell neogenesis (P. Collombat, University Nice Sophia Antipolis)
  • Epigenetic reprogramming of alpha- to beta-cells (K. Kaestner, University of Pennsylvania)

Session 4: The stressful life of the diabetic cell (3:30 pm to 5:30 pm)
  • How does an increase in insulin production cause beta cell failure (R. Kaufman, Sanford-Burnham Medical Research Institute)
  • Protein misfolding and beta cell stress (P. Arvan, University of Michigan)
  • Beta cell inflammation and ER stress (A. Cardozo, Universite Libre de Bruxelles)
  • Calcium signaling and ER stress in obesity and type 2 diabetes (I. Tabas, Columbia University)
 
Debate: Virus? What virus? (5:45 pm to 6:55 pm)
  • (B. Roep, Leiden University Medical Center)
  • (M. von Herrath, La Jolla Institute for Allergy and Immunology)

WEDNESDAY, MARCH 4, 2015
 
Session 1: Type 1 diabetes biomarkers (8:00 am to 10:00 am)
  • Validation efforts with the JDRF Biomarker Working Group (J. Odegard, Benaroya Research Institute)
  • Type 1 diabetes biomarkers (T. Brusko, University of Florida)
  • Biomarkers from recent onset clinical trials (P. Gottlieb, University of Colorado)
  • Recognition of post-translationally modified antigens as biomarkers in type 1 diabetes (E. James, Benaroya Research Institute)
 
Session 2: Diabetes technology updates (10:20 am to 12:20 pm)
  • Novel insulin formulations (M. Weiss, Case Western Reserve University)
  • Foreign body and inflammatory response to implanted sensors (N. Wisniewski, PROFUSA, Inc.)
  • Intravascular glucose sensors (J. Joseph, Thomas Jefferson University)
  • Long-term implanted glucose sensors (D. Gough, University of California San Diego)
     
Session 3: Novel approaches to understanding and treating hypoglycemia (12:40 pm to 2:40 pm)
  • Cerebral adaptation to recurrent hypoglycemia (R. McCrimmon, University of Dundee)
  • Preventing hypoglycemia-induced morbidity and mortality (S. Fisher, University of Utah)
  • Hypoglycemia-induced cardiac arrhythmias (S. Heller, University of Sheffield)
  • Psychological factors and behavioral approaches in patients with hypoglycemia unawareness (L. Gonder-Frederick, University of Virginia Health System)
 
Plenary Lecture (2:40 pm to 3:15 pm)
  • Outcomes from the CIT trial (A. Naji, University of Pennsylvania)
 

March 13, 2013 Schedule

Session 1: Diabetic complications (8:00 am to 10:00 am)
Moderator
Rama Natarajan, Ph.D.( City of Hope , Duarte, CA)

Advanced glycation: AGE – RAGE and diabetic vascular complications
Ann Marie Schmidt, M.D.(Columbia University College of Physicians & Surgeons, New York, NY)

Stem cell approaches for vascular repair in diabetic retinopathy
Maria B. Grant, M.D.(University of Florida, Gainesville, FL)

Systems biology of diabetic kidney disease: Lessons learnt from animal and human models
Matthias Kretzler, M.D.(University of Michigan, Ann Arbor, MI)

Advances in drugs and drug targets for diabetic vascular complications, to ACE or ARB?
Mark Cooper, MBBS, Ph.D., FRACP(Baker ID Heart and Diabetes Institute, Melbourne Australia)

Plenary Lecture (10:15 am to 10:45 am)
Developing a combination cell therapy and delivery device for insulin-dependent diabetes
Eugene Brandon,Ph.D.(Viacyte, San Diego, CA)

Session 2:Clinical trials for type 1 diabetes(11:00 am to 1:00 pm)
Moderator
Matthias von Herrath, M.D. (La Jolla Institute for Allergy and Immunology, La Jolla, CA)

Optimal trial design in T1D
Richard Insel, M.D. (JDRF, New York, NY)

All recent-onset trials look the same, or do they?
David Harlan, M.D. (University of Massachusetts School of Medicine, Worcester, MA)

Anti-cytokine therapies overall
Mario Ehlers, M.D., Ph.D.(Immune Tolerance Network, San Francisco, CA)

High dose oral insulin in babies
Ezio Bonifacio, Ph.D.(DFG-Center for Regenerative Therapies Dresden, Dresden, Germany)

Session 3: Artificial pancreas (2:15 pm to 4:15 pm)
Moderator
Howard Zisser, M.D. (Sansum Diabetes Research Institute, Santa Barbara, CA)

System and control engineering for type 1 diabetes
Frank Doyle, Ph.D. (UCSB, Santa Barbara, CA)

The use of an automated glucose control system for overnight glucose control in adolescents with type 1 diabetes
Timothy Jones, M.D. (Princess Margaret Hospital, Perth, Australia)

Intensive insulin therapy using an artificial pancreas with closed-loop system
Kazuhiro Hanazaki, M.D., Ph.D.(Kochi Medical School, Kochi, Japan)

Implantable sensors - Animal data
Daniel Burnett, M.D. (TheraNova, LLC, San Francisco, CA)

Dinner and Presentation of Awards(5:30 pm to 7:00 pm)
Samuel Rahbar, M.D., Ph.D. Memorial Lecture
Fouad Kandeel, M.D., Ph.D. (City of Hope, Duarte, CA)

March 14, 2013 Schedule

Session 1: Epigenetics (8:00 am to 10:00 am)
Moderator
Rama Natarajan, Ph.D. (City of Hope, Duarte, CA)

Rodent models of epigenetic regulation of insulin resistance and diabetes
Rebecca Simmons, M.D.(Children's Hospital of Philadelphia, Philadelphia, PA)

 

Epigenomics of development and disease
Dustin Schones, Ph.D. (City of Hope, Duarte, CA)

 

Epigenetic regulation of alpha vs. beta cells
Anil Bhushan, Ph.D.(UCLA, Los Angeles, CA)

Beyondgenetics: The epigenetic code in chronic diabetic kidney disease
Dominic Raj, M.D. (George Washington University, Washington, DC)

Plenary Lecture (10:15 am to 10:45 am)
FoXO1, insulin action and metabolic effects
Domenico Accili, M.D.(Columbia University, New York, NY)

Session 2:Diabetes and the gut microbiome (11:00 am to 12:35 pm)
Moderator
Olle Korsgren, M.D., Ph.D. (Uppsala University Hospital, Uppsala, Sweden)

 

Bacteria reflux talk contributing to T1D
Olle Korsgren, M.D.,Ph.D.(Uppsala University Hospital, Uppsala, Sweden)

 

Fecal transplant talk – bridging T1D and T2D
Max Nieuwdorp, M.D., Ph.D.(Academic Medical Center-UvA, Amsterdam, The Netherlands)

 

Stopping autoimmune disease in type 1 diabetes: Exploiting the gut immune system
Chantal Mathieu, M.D., Ph.D. (Katholieke Universiteit, Leuven, Belgium)

Session 3: Islet imaging (2:00 pm to 4:00 pm)
Moderators
Al Powers, M.D.(Vanderbilt University, Nashville, TN)

 

The status of human beta cell specific monoclonal antibodies
Markus Grompe, M.D. (Oregon Health & Science University, Portland, OR)

Bioluminescent imaging of human pancreas islets
Jack Virostko, Ph.D.(Vanderbilt University, Nashville, TN)

 

Beta cell-specific imaging with zinc probes
A. Dean Sherry, Ph.D.(UT Southwestern, Dallas, TX)

 

VMAT2 ligand imaging of human beta cells in vivo
Gary Cline, Ph.D.(Yale University, New Haven, CT)

 

Poster Session (4:00 pm to 6:00 pm)

 

 

 

March 15, 2013 Schedule

Session 1: Glucose metabolism , beta cell biology and cancer (8:00 am to 10:00 am)
Moderator
David Harlan, M.D. (University of Massachusetts School of Medicine, Worcester, MA)

 

PTEN at the intersection of diabetes and cancer
Bangyan Stiles, Ph.D.(USC, Los Angeles, CA)

 

Glucose metabolism, ChREBP and proliferation in the beta cell
Donald Scott, Ph.D. (University of Pittsburgh, Pittsburgh, PA)

The putative association between glargine insulin and cancer
James Meigs, M.D. (Massachusetts General Hospital, Boston, MA)

 

RLIP76, a glutathione-conjugate transporter, plays a major role in cancer and the metabolic syndrome
Sanjay Awasthi, M.D. ( City of Hope , Duarte, CA)

Plenary lecture (10:15 am to 10:45 am)
Dysfunctional hematopoietic cells mediate chronic diabetic complications
Lawrence Chan, M.D. (Baylor College of Medicine, Houston, TX)

 

Session 2: Reversal of autoimmunity and transplantation tolerance (11:00 am to 1:00 pm)
Moderator
Bart Roep, M.D., Ph.D.(Leiden University Medical Center, Leiden, The Netherlands)

 

Reversal of autoimmunity via induction of mixed chimerism under a radiation-free anti-CD3/CD8 conditioning
Defu Zeng, Ph.D.(City of Hope, Duarte, CA)

 

Tolerance to organ transplants in humans
Samuel Strober, M.D.(Stanford University, Stanford, CA)

 

MSCs potential in clinical islet transplantation therapy
Yoko Mullen, M.D., Ph.D. (City of Hope, Duarte, CA)

MSC in T2D
Antonello Pileggi, M.D., Ph.D. (University of Miami, Miami, FL)

 

Debate: Is there evidence for distinct courses in loss of beta-cell function in T1D?(2:15 pm to 3:15 pm)
Moderator
Bart Roep, M.D., Ph.D.(Leiden University Medical Center, Leiden, The Netherlands)

Position 1
Carla Greenbaum, M.D. (Benaroya Research Institute at Virginia Mason, Seattle, WA)

Position 2
Kevan Herold, M.D. (Yale University, New Haven, CT)

 

Inflammation, macrophages and ER stress (3:30 pm to 5:30 pm)
Moderator
Janice Huss, Ph.D. (City of Hope, Duarte, CA)

Diabetes -accelerated atherosclerosis and inflammation - Revealing the picture one piece at a time
Karin Bornfeldt, Ph.D.(University of Washington, Seattle, WA)

 

Beta-cell suicide
Feroz Papa, M.D., Ph.D.(UCSF, San Francisco, CA)

 

Immunologic regulation of adipose tissue function
Anthony W. Ferrante, M.D., Ph.D. (Columbia University, New York, NY)

Regulatory myeloid cells mediated immune suppression vs. inflammation
Shu-Hsia Chen, Ph.D. (Mount Sinai School of Medicine, New York, NY)

 

March 16, 2013 Schedule

Session 1: Human pancreas development (8:00 am to 10:00 am)
Moderator
Andrew Stewart, M.D. (Mount Sinai School of Medicine, New York, NY)

 

A careful look at human endocrine pancreas development: Part 1
Marcela Brissova, Ph.D. (Vanderbilt University, Nashville, TN)

 

A careful look at human endocrine pancreas development: Part 2
Philip DiIorio, Ph.D. (University of Massachusetts School of Medicine, Worcester, MA)

 

Endocrine pancreas development in the non-human primate pancreas
Lynley Pound, Ph.D. (Oregon National Primate Research Center, Beaverton, OR)

Development of authentic human beta cell lines
Philippe Ravassard,Ph.D. (ICM-INSERM, Paris, France)

Debate: The beta-cell will be preserved with currently available therapy in type 2 diabetes(10:15 am to 11:15 am)
Moderator
Robert Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)

Position 1
Philip Raskin, M.D. (UT Southwestern Medical Center, Dallas, TX)

Position 2
John Leahy, M.D. (University of Vermont, Colchester, VT)

 

Session 2: Clinical controversies in diabetes care (11:30 am to 1:30 pm)
Moderator
Fouad Kandeel, M.D., Ph.D. (City of Hope, Duarte, CA)

 

Glycemic control diabetes complications: Implications for care in the post-ACCORD era
David Kendall, M.D. (Lilly Diabetes, Minneapolis, MN)

DCCT/EDIC Research Group update
John M. Lachin, Sc.D. (The George Washington University, Rockville, MD)

Use of bariatric surgery to cure diabetes
Philip Schauer, M.D. (Cleveland Clinic, Cleveland, OH)

Glycemic variability
Robert Vigersky, M.D.(Walter Reed National Military Medical Center, Washington, DC)

 

 

Program

Program

SUNDAY, MARCH 1, 2015

Session 1: Diabetes complications: New biomarkers and drug targets (12:00 pm to 2:00 pm)
  • New treatments for diabetic complications: Results from high throughtput screening and in silico modeling (A. Schmidt, NYU Langone Medical Center)
  • New therapies and biomarkers for diabetic complications: Lessons learnt from omics profiling (K. Sharma, University of California San Diego)
  • RAGE and retinal disease: Roles in diabetic retinopathy (A. Stitt, Queen's University Belfast)
  • Transcription factor acetylation in diabetic glomerulopathy (J. He, Mount Sinai Hospital)
 
Session 2: Personalized medicine in future diabetes care (2:20 pm to 4:20 pm)
  • Personalized medicine: The future is now (E. Bottinger, Icahn School of Medicine Mount Sinai)
  • Using public big-data to discover new therapeutic and genetic insights in diabetes (A. Butte, University of California San Francisco)
  • Pharmacogenetics and precision medicine in type 2 diabetes: Potential implications for clinical practice (J. Florez, Massachusetts General Hospital)
  • Systems genetics of diabetic nephropathy (M. Kretzler, University of Michigan)

Oral Presentations (4:30 pm)
 
Presentation of Awards and Dinner Lecture (6:30 pm)
  • Type 1 diabetes: Adults vs. kids (C. Greenbaum, Benaroya Research Institute)

MONDAY, MARCH 2, 2015
 
Rachmiel Levine Award Lecture (7:30 am)
  • Evolving concepts of incretin action inform the treatment of metabolic disorders (D. Drucker, Lunenfeld Tanenbaum Research Institute)
 
Session 1: Epigenetics of diabetes (8:00 am to 10:00 am)
  • Epigenomics of insulin resistance (E. Rosen, Beth Israel Deaconess Medical Center)
  • Epigenetic mechanisms in diabetic complications and metabolic memory (R. Natarajan, Beckman Research Institute of City of Hope)
  • Hyperglycemia-induced Dnmt activity leading to diabetic embryopathy (M. Loeken, Joslin Diabetes Center)
  • Epigenetics and beta cell identity (M. Sander, University of California San Diego)
 
Session 2: Obesity and inflammation (10:20 am to 12:20 pm)
  • Obesity and immune system (M. Bluher, University Hospital Leipzig)
  • Macrophage lysosome dysfunction in diabetic inflammation (J. Schilling, Washington University)
  • Macrophages, insulin resistance and immunometabolism (A. Ferrante, Columbia University)
  • Macrophages and vitamin D metabolism in diabetes (C. Bernal-Mizrachi, Washington University)
 
Session 3: Metabolism and inflammation (1:30 pm to 3:30 pm)
  • Metabolic signatures in the development of insulin resistance (C. Newgard, Duke University)
  • Epigenetics, metabolism and the circadian clock (P. Sassone-Corsi, University of California Irvine)
  • Innate mechanisms of metabolic homeostasis (A. Chawla, University of California San Francisco)
  • Targeting neuroinflammation for diabetes treatment (M. Tschop, Helmholtz Diabetes Center)
 
Debate: Can adult human beta cells proliferate? (3:50 pm to 5:00 pm)
  • (A. Stewart, Mount Sinai School of Medicine)
  • (D. Harlan, University of Massachusetts)
 
Plenary Lecture (5:00 pm to 5:35 pm)
  • 30 year history of the DCCT: Patient pursuit of a chronic disease (D. Nathan, Massachusetts General Hospital)
 
Poster Session (5:35 pm)

TUESDAY, MARCH 3, 2015
 
Session 1: Lessons from human insulinoma for beta cell regeneration (8:00 am to 10:00 am)
  • The role of YY1 in human insulinoma pathogenesis (G. Ning, Shanghai Institute for Endocrine and Metabolic Diseases)
  • Novel insulinoma-genic molecular pathways (T. Carling, Yale University)
  • RNA profiling of human insulinomas for beta cell regeneration strategies (A. Stewart, Mount Sinai School of Medicine)
  • Non-coding genome function in the developing human pancreas (J. Ferrer, Imperial College London)
 
Session 2: Novel molecules that induce human beta cell replication (10:20 am to 12:20 pm)
  • Liver-derived beta cell regenerative factors (R. Kulkarni, Joslin Diabetes Center)
  • Novel therapeutic epigenetic modulators of human beta cell replication (A. Bhushan, University of California San Francisco)
  • Small-molecule inducers of human beta-cell proliferation (B. Wagner, Broad Institute)
  • High-throughput screening for small-molecule inducers of beta-cell proliferation (P. Wang, Mount Sinai School of Medicine)
 
Arthur Riggs Award Lecture (1:40 pm)
  • The new biology of beta cell failure (D. Accili, Columbia University)
 
Session 3: Reprogramming islet cells to beta cells (2:10 pm to 3:10 pm)
  • In vivo induction of alpha-cell-mediated beta-like cell neogenesis (P. Collombat, University Nice Sophia Antipolis)
  • Epigenetic reprogramming of alpha- to beta-cells (K. Kaestner, University of Pennsylvania)

Session 4: The stressful life of the diabetic cell (3:30 pm to 5:30 pm)
  • How does an increase in insulin production cause beta cell failure (R. Kaufman, Sanford-Burnham Medical Research Institute)
  • Protein misfolding and beta cell stress (P. Arvan, University of Michigan)
  • Beta cell inflammation and ER stress (A. Cardozo, Universite Libre de Bruxelles)
  • Calcium signaling and ER stress in obesity and type 2 diabetes (I. Tabas, Columbia University)
 
Debate: Virus? What virus? (5:45 pm to 6:55 pm)
  • (B. Roep, Leiden University Medical Center)
  • (M. von Herrath, La Jolla Institute for Allergy and Immunology)

WEDNESDAY, MARCH 4, 2015
 
Session 1: Type 1 diabetes biomarkers (8:00 am to 10:00 am)
  • Validation efforts with the JDRF Biomarker Working Group (J. Odegard, Benaroya Research Institute)
  • Type 1 diabetes biomarkers (T. Brusko, University of Florida)
  • Biomarkers from recent onset clinical trials (P. Gottlieb, University of Colorado)
  • Recognition of post-translationally modified antigens as biomarkers in type 1 diabetes (E. James, Benaroya Research Institute)
 
Session 2: Diabetes technology updates (10:20 am to 12:20 pm)
  • Novel insulin formulations (M. Weiss, Case Western Reserve University)
  • Foreign body and inflammatory response to implanted sensors (N. Wisniewski, PROFUSA, Inc.)
  • Intravascular glucose sensors (J. Joseph, Thomas Jefferson University)
  • Long-term implanted glucose sensors (D. Gough, University of California San Diego)
     
Session 3: Novel approaches to understanding and treating hypoglycemia (12:40 pm to 2:40 pm)
  • Cerebral adaptation to recurrent hypoglycemia (R. McCrimmon, University of Dundee)
  • Preventing hypoglycemia-induced morbidity and mortality (S. Fisher, University of Utah)
  • Hypoglycemia-induced cardiac arrhythmias (S. Heller, University of Sheffield)
  • Psychological factors and behavioral approaches in patients with hypoglycemia unawareness (L. Gonder-Frederick, University of Virginia Health System)
 
Plenary Lecture (2:40 pm to 3:15 pm)
  • Outcomes from the CIT trial (A. Naji, University of Pennsylvania)
 

March 13, 2013 Schedule

March 13, 2013 Schedule

Session 1: Diabetic complications (8:00 am to 10:00 am)
Moderator
Rama Natarajan, Ph.D.( City of Hope , Duarte, CA)

Advanced glycation: AGE – RAGE and diabetic vascular complications
Ann Marie Schmidt, M.D.(Columbia University College of Physicians & Surgeons, New York, NY)

Stem cell approaches for vascular repair in diabetic retinopathy
Maria B. Grant, M.D.(University of Florida, Gainesville, FL)

Systems biology of diabetic kidney disease: Lessons learnt from animal and human models
Matthias Kretzler, M.D.(University of Michigan, Ann Arbor, MI)

Advances in drugs and drug targets for diabetic vascular complications, to ACE or ARB?
Mark Cooper, MBBS, Ph.D., FRACP(Baker ID Heart and Diabetes Institute, Melbourne Australia)

Plenary Lecture (10:15 am to 10:45 am)
Developing a combination cell therapy and delivery device for insulin-dependent diabetes
Eugene Brandon,Ph.D.(Viacyte, San Diego, CA)

Session 2:Clinical trials for type 1 diabetes(11:00 am to 1:00 pm)
Moderator
Matthias von Herrath, M.D. (La Jolla Institute for Allergy and Immunology, La Jolla, CA)

Optimal trial design in T1D
Richard Insel, M.D. (JDRF, New York, NY)

All recent-onset trials look the same, or do they?
David Harlan, M.D. (University of Massachusetts School of Medicine, Worcester, MA)

Anti-cytokine therapies overall
Mario Ehlers, M.D., Ph.D.(Immune Tolerance Network, San Francisco, CA)

High dose oral insulin in babies
Ezio Bonifacio, Ph.D.(DFG-Center for Regenerative Therapies Dresden, Dresden, Germany)

Session 3: Artificial pancreas (2:15 pm to 4:15 pm)
Moderator
Howard Zisser, M.D. (Sansum Diabetes Research Institute, Santa Barbara, CA)

System and control engineering for type 1 diabetes
Frank Doyle, Ph.D. (UCSB, Santa Barbara, CA)

The use of an automated glucose control system for overnight glucose control in adolescents with type 1 diabetes
Timothy Jones, M.D. (Princess Margaret Hospital, Perth, Australia)

Intensive insulin therapy using an artificial pancreas with closed-loop system
Kazuhiro Hanazaki, M.D., Ph.D.(Kochi Medical School, Kochi, Japan)

Implantable sensors - Animal data
Daniel Burnett, M.D. (TheraNova, LLC, San Francisco, CA)

Dinner and Presentation of Awards(5:30 pm to 7:00 pm)
Samuel Rahbar, M.D., Ph.D. Memorial Lecture
Fouad Kandeel, M.D., Ph.D. (City of Hope, Duarte, CA)

March 14, 2013 Schedule

March 14, 2013 Schedule

Session 1: Epigenetics (8:00 am to 10:00 am)
Moderator
Rama Natarajan, Ph.D. (City of Hope, Duarte, CA)

Rodent models of epigenetic regulation of insulin resistance and diabetes
Rebecca Simmons, M.D.(Children's Hospital of Philadelphia, Philadelphia, PA)

 

Epigenomics of development and disease
Dustin Schones, Ph.D. (City of Hope, Duarte, CA)

 

Epigenetic regulation of alpha vs. beta cells
Anil Bhushan, Ph.D.(UCLA, Los Angeles, CA)

Beyondgenetics: The epigenetic code in chronic diabetic kidney disease
Dominic Raj, M.D. (George Washington University, Washington, DC)

Plenary Lecture (10:15 am to 10:45 am)
FoXO1, insulin action and metabolic effects
Domenico Accili, M.D.(Columbia University, New York, NY)

Session 2:Diabetes and the gut microbiome (11:00 am to 12:35 pm)
Moderator
Olle Korsgren, M.D., Ph.D. (Uppsala University Hospital, Uppsala, Sweden)

 

Bacteria reflux talk contributing to T1D
Olle Korsgren, M.D.,Ph.D.(Uppsala University Hospital, Uppsala, Sweden)

 

Fecal transplant talk – bridging T1D and T2D
Max Nieuwdorp, M.D., Ph.D.(Academic Medical Center-UvA, Amsterdam, The Netherlands)

 

Stopping autoimmune disease in type 1 diabetes: Exploiting the gut immune system
Chantal Mathieu, M.D., Ph.D. (Katholieke Universiteit, Leuven, Belgium)

Session 3: Islet imaging (2:00 pm to 4:00 pm)
Moderators
Al Powers, M.D.(Vanderbilt University, Nashville, TN)

 

The status of human beta cell specific monoclonal antibodies
Markus Grompe, M.D. (Oregon Health & Science University, Portland, OR)

Bioluminescent imaging of human pancreas islets
Jack Virostko, Ph.D.(Vanderbilt University, Nashville, TN)

 

Beta cell-specific imaging with zinc probes
A. Dean Sherry, Ph.D.(UT Southwestern, Dallas, TX)

 

VMAT2 ligand imaging of human beta cells in vivo
Gary Cline, Ph.D.(Yale University, New Haven, CT)

 

Poster Session (4:00 pm to 6:00 pm)

 

 

 

March 15, 2013 Schedule

March 15, 2013 Schedule

Session 1: Glucose metabolism , beta cell biology and cancer (8:00 am to 10:00 am)
Moderator
David Harlan, M.D. (University of Massachusetts School of Medicine, Worcester, MA)

 

PTEN at the intersection of diabetes and cancer
Bangyan Stiles, Ph.D.(USC, Los Angeles, CA)

 

Glucose metabolism, ChREBP and proliferation in the beta cell
Donald Scott, Ph.D. (University of Pittsburgh, Pittsburgh, PA)

The putative association between glargine insulin and cancer
James Meigs, M.D. (Massachusetts General Hospital, Boston, MA)

 

RLIP76, a glutathione-conjugate transporter, plays a major role in cancer and the metabolic syndrome
Sanjay Awasthi, M.D. ( City of Hope , Duarte, CA)

Plenary lecture (10:15 am to 10:45 am)
Dysfunctional hematopoietic cells mediate chronic diabetic complications
Lawrence Chan, M.D. (Baylor College of Medicine, Houston, TX)

 

Session 2: Reversal of autoimmunity and transplantation tolerance (11:00 am to 1:00 pm)
Moderator
Bart Roep, M.D., Ph.D.(Leiden University Medical Center, Leiden, The Netherlands)

 

Reversal of autoimmunity via induction of mixed chimerism under a radiation-free anti-CD3/CD8 conditioning
Defu Zeng, Ph.D.(City of Hope, Duarte, CA)

 

Tolerance to organ transplants in humans
Samuel Strober, M.D.(Stanford University, Stanford, CA)

 

MSCs potential in clinical islet transplantation therapy
Yoko Mullen, M.D., Ph.D. (City of Hope, Duarte, CA)

MSC in T2D
Antonello Pileggi, M.D., Ph.D. (University of Miami, Miami, FL)

 

Debate: Is there evidence for distinct courses in loss of beta-cell function in T1D?(2:15 pm to 3:15 pm)
Moderator
Bart Roep, M.D., Ph.D.(Leiden University Medical Center, Leiden, The Netherlands)

Position 1
Carla Greenbaum, M.D. (Benaroya Research Institute at Virginia Mason, Seattle, WA)

Position 2
Kevan Herold, M.D. (Yale University, New Haven, CT)

 

Inflammation, macrophages and ER stress (3:30 pm to 5:30 pm)
Moderator
Janice Huss, Ph.D. (City of Hope, Duarte, CA)

Diabetes -accelerated atherosclerosis and inflammation - Revealing the picture one piece at a time
Karin Bornfeldt, Ph.D.(University of Washington, Seattle, WA)

 

Beta-cell suicide
Feroz Papa, M.D., Ph.D.(UCSF, San Francisco, CA)

 

Immunologic regulation of adipose tissue function
Anthony W. Ferrante, M.D., Ph.D. (Columbia University, New York, NY)

Regulatory myeloid cells mediated immune suppression vs. inflammation
Shu-Hsia Chen, Ph.D. (Mount Sinai School of Medicine, New York, NY)

 

March 16, 2013 Schedule

March 16, 2013 Schedule

Session 1: Human pancreas development (8:00 am to 10:00 am)
Moderator
Andrew Stewart, M.D. (Mount Sinai School of Medicine, New York, NY)

 

A careful look at human endocrine pancreas development: Part 1
Marcela Brissova, Ph.D. (Vanderbilt University, Nashville, TN)

 

A careful look at human endocrine pancreas development: Part 2
Philip DiIorio, Ph.D. (University of Massachusetts School of Medicine, Worcester, MA)

 

Endocrine pancreas development in the non-human primate pancreas
Lynley Pound, Ph.D. (Oregon National Primate Research Center, Beaverton, OR)

Development of authentic human beta cell lines
Philippe Ravassard,Ph.D. (ICM-INSERM, Paris, France)

Debate: The beta-cell will be preserved with currently available therapy in type 2 diabetes(10:15 am to 11:15 am)
Moderator
Robert Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)

Position 1
Philip Raskin, M.D. (UT Southwestern Medical Center, Dallas, TX)

Position 2
John Leahy, M.D. (University of Vermont, Colchester, VT)

 

Session 2: Clinical controversies in diabetes care (11:30 am to 1:30 pm)
Moderator
Fouad Kandeel, M.D., Ph.D. (City of Hope, Duarte, CA)

 

Glycemic control diabetes complications: Implications for care in the post-ACCORD era
David Kendall, M.D. (Lilly Diabetes, Minneapolis, MN)

DCCT/EDIC Research Group update
John M. Lachin, Sc.D. (The George Washington University, Rockville, MD)

Use of bariatric surgery to cure diabetes
Philip Schauer, M.D. (Cleveland Clinic, Cleveland, OH)

Glycemic variability
Robert Vigersky, M.D.(Walter Reed National Military Medical Center, Washington, DC)

 

 
City of Hope combines compassionate care with the best and most innovative science. Our 100+ acre campus is designed to meet the full range of needs of our patients and families. This guide is designed to help you take advantage of all that is offered at City of Hope - Duarte.
To make an appointment for yourself, a family member or a friend, please complete and submit our Become a Patient Request Form, or call City of Hope at
800-826-HOPE (4673).
Contact Us
Phone: (800) 826-HOPE (4673)
 
Hours: M – F, 8 a.m. to 5 p.m. (PST)
 
Calls received after 5 p.m. will be returned the next business day.
Patient Care Overview

Info for Referring Physicians
City of hope welcomes patient referrals from physicians throughout the world. City of Hope is located near northeast Los Angeles, in Duarte, California.